Author:
Armoiry Xavier,Connock Martin,Tsertsvadze Alexander,Cummins Ewen,Melendez-Torres G. J.,Royle Pam,Clarke Aileen
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference15 articles.
1. Ixazomib citrate in combination with lenalidomide and dexamethasone for relapsed refractory multiple myeloma: a single technology appraisal. Warwick Evidence; 2017.
2. Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008;33(3):219–26.
3. Haematological Malignancy Research Network (HMRN). Myeloma. 2017.
https://www.hmrn.org/statistics/disorders/24
. Accessed 21 Feb 2017.
4. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.
5. Cartier S, Zhang B, Rosen VM, Zarotsky V, Bartlett JB, Mukhopadhyay P, et al. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data. Oncol Res Treat. 2015;38(3):88–94.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献